Find participating medical centers and current study status in each of them

    Find participating medical centers

    A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

    • Cancer
    • Multiple Myeloma